Antihypertensive effects of the putative T-type calcium channel antagonist mibefradil are mediated by the L-type calcium channel Cav1.2

Circ Res. 2006 Jan 6;98(1):105-10. doi: 10.1161/01.RES.0000197851.11031.9c. Epub 2005 Nov 23.

Abstract

The role of T-type Ca2+ channels for cardiovascular physiology, in particular blood pressure regulation, is controversial. Selective blockade of T-type Ca2+ channels in resistance arteries has been proposed to explain the effect of the antihypertensive drug mibefradil. In the present study, we used a third generation, time- and tissue-specific conditional knockout model of the L-type Ca2+ channel Cav1.2 (Cav1.2SMAKO mice) to genetically dissect the effects of mibefradil on T- and L-type Ca2+ channels. Myogenic tone and phenylephrine-induced contraction in hindlimb perfusion experiments were sensitive to mibefradil in control mice, whereas the drug showed no effect in Cav1.2-deficient animals. Mean arterial blood pressure in awake, freely moving control mice was reduced by 38+/-2.5 mm Hg at a dose of 1.25 mg/kg bodyweight mibefradil, but not changed in Cav1.2SMAKO mice. These results demonstrate that the effect of the putative T-type Ca2+ channel-selective blocker mibefradil on blood pressure and small vessel myogenic tone is mediated by the Cav1.2 L-type Ca2+ channel.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antihypertensive Agents / pharmacology*
  • Blood Pressure / drug effects
  • Calcium Channel Blockers / pharmacology*
  • Calcium Channels, L-Type / physiology*
  • Calcium Channels, T-Type / physiology*
  • Male
  • Membrane Potentials
  • Mibefradil / pharmacology*
  • Mice
  • Mice, Inbred C57BL
  • Muscle, Smooth, Vascular / physiology

Substances

  • Antihypertensive Agents
  • Calcium Channel Blockers
  • Calcium Channels, L-Type
  • Calcium Channels, T-Type
  • L-type calcium channel alpha(1C)
  • Mibefradil